18F-DCFPyL PSMA PET/CT Tracheobronchial Uptake in Patients with Prostate Cancer: Incidence and Etiology

• DOI: 10.2967/jnumed.124.267772
• Publication Date: 2024-08-01T18:45:53Z
• Authors: Medhat M. Osman; Amir Iravani; Catherine Mitchell; Rodney J. Hicks; Elisa Perry; Michael S. Hofman
• Keywords: Male; Glutamate Carboxypeptidase II; Aged, 80 and over; Lysine; Prostatic Neoplasms; Bronchi; Biological Transport; Middle Aged; Brief Communication; Trachea; Positron Emission Tomography Computed Tomography; Antigens, Surface; Humans; Urea; Radiopharmaceuticals; Aged; Retrospective Studies

We evaluated the incidence and potential etiology of tracheobronchial uptake in patients being evaluated by 18F-DCFPyL PET/CT for prostate cancer (PCa). Methods: The study included a consecutive 100 PCa patients referred for 18F-DCFPyL PET/CT. The PET/CT scans were retrospectively reviewed. The presence or absence of physiologic tracheobronchial uptake on PET/CT was recorded. To further evaluate tracheal prostate-specific membrane antigen (PSMA) expression, immunohistochemistry was performed on tracheal samples taken from 2 men who had surgical resection of lung cancer. Results: Tracheal uptake was present in 31 of 100 patients (31%). When tracheal uptake was present, the SUVmax was significantly higher in the left main bronchus (mean, 2.7) than in the right (mean, 2.3) (P < 0.001). Histopathologic testing of tracheobronchial samples showed PSMA expression in bronchial submucosal glands. Conclusion: In PCa patients undergoing 18F-DCFPyL PET/CT, tracheobronchial uptake occurred in 31% of patients. This is attributed to normal physiologic PSMA expression in bronchial submucosal glands.